|
Jul 22
|
Why Replimune's Surprise Rejection Rattled Wall Street, And Cratered Its Stock
|
|
Jul 22
|
Top Midday Decliners
|
|
Jul 22
|
Replimune Could Need 'Significant Restructuring' for RP1 Study Changes, Wedbush Says
|
|
Jul 22
|
Replimune Stock Plummets 75% After FDA Rejects Application for Skin Cancer Treatment
|
|
Jul 22
|
BC-Most Active Stocks
|
|
Jul 22
|
FDA Rejects Replimune’s Skin Cancer Treatment, Shares Sink
|
|
Jul 22
|
Replimune's Melanoma Therapy Denied FDA Approval, Shares Fall Sharply
|
|
Jul 22
|
Replimune drug rejected by FDA; Omega raises $647M biotech fund
|
|
Jul 22
|
Replimune Receives Complete Response Letter from FDA for RP1 Biologics License Application for the Treatment of Advanced Melanoma
|
|
Jun 1
|
Replimune Presents New Analyses from the IGNYTE Study of RP1 plus Nivolumab in Anti-PD1 Failed Melanoma at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
|
|
May 29
|
Replimune to Present at the 2025 Jefferies Global Healthcare Conference
|
|
Mar 7
|
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
|
Feb 12
|
Replimune Reports Fiscal Third Quarter 2025 Financial Results and Provides Corporate Update
|